PP
GNMX

Paloma Partners’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Paloma Partners’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-98,300
Closed -$131K – 2610
2017
Q2 		$131K Buy
+98,300
New +$142K ﹤0.01% 2055

Other funds holding GNMX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NCMW
Northern Capital Management (Wisconsin) Madison, Wisconsin $373M AUM 11.01% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Paloma Partners's GNMX Position: Q3 2017 in Review

Paloma Partners sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2017, closing a stake of 98,300 shares — an estimated $131K sold.

Paloma Partners first reported a position in GNMX in Q2 2017 and held it in 1 quarter. The position peaked at $131K in Q2 2017. 49 funds tracked by Wall St. Rank hold GNMX as of Q3 2017.

  • Paloma Partners reported no remaining Aevi Genomic Medicine Inc position as of Q3 2017 after selling out during the quarter.
  • Paloma Partners sold 98,300 Aevi Genomic Medicine Inc shares in Q3 2017, an estimated $131K.
  • Paloma Partners first reported a position in Aevi Genomic Medicine Inc in Q2 2017 and held it in 1 quarter.
  • Paloma Partners's Aevi Genomic Medicine Inc position peaked at $131K in Q2 2017.
  • 49 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.